Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
metastatic castration-resistant prostate cancer treatment
market8 mentionslast seen Nov 3, 2026
Market for advanced treatment of prostate cancer resistant to castration therapy.
Relationships 6
- ENV-105applies tometastatic castration-resistant prostate cancer treatment99% confidence2 sources
- PDS0301applies tometastatic castration-resistant prostate cancer treatment99% confidence2 sources
- VIR-5500applies tometastatic castration-resistant prostate cancer treatment95% confidence1 source
- ATNM-400applies tometastatic castration-resistant prostate cancer treatment90% confidence1 source
- ADI-212applies tometastatic castration-resistant prostate cancer treatment85% confidence1 source
- REVTORPYKapplies tometastatic castration-resistant prostate cancer treatment85% confidence1 source
Relationship
ENV-105applies tometastatic castration-resistant prostate cancer treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 3, 2026Kairos Pharma, LTD. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
- filingSEC EDGAROct 6, 2026Kairos Pharma, LTD. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)